Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 10/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658459 | 0.86 | JAK2 (0.42) | CHRM5CHRM1CHRM3CHRM4JAK2 | |
| SCHEMBL24962330 | 0.85 | GPR119 (0.44) | AAK1CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL19652119 | 0.85 | AAK1 (0.42) | AAK1GPR119 | |
| SCHEMBL19652137 | 0.79 | CTSS (0.48) | AAK1CHRM4CHRM2GPR119 | |
| SCHEMBL17753766 | 0.77 | JAK3 (0.40) | CHRM5CHRM1CHRM3CHRM4JAK2 | |
| SCHEMBL19652156 | 0.77 | SSTR4 (0.49) | CHRM5CHRM1CHRM3CHRM4TP53 | |
| SCHEMBL3667948 | 0.75 | AOC3 (0.37) | JAK3 | |
| SCHEMBL19652198 | 0.74 | GPR119 (0.59) | AAK1GPR119 | |
| SCHEMBL19652111 | 0.73 | KDM4E (0.51) | — | |
| SCHEMBL19652105 | 0.72 | KDM4E (0.54) | TP53GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | AAK1 2725/4885CHRM5 1660/4885CHRM1 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.